A Randomized, Double-blinded, Placebo-controlled, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of TLL018 in Participants With Moderate-to-severe Plaque Psoriasis
Latest Information Update: 30 Dec 2024
Price :
$35 *
At a glance
- Drugs TLL 018 (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Hangzhou Highlightll Pharmaceutical
- 27 Dec 2024 Status changed from recruiting to completed.
- 20 Sep 2023 Planned End Date changed from 30 Sep 2023 to 31 May 2024.
- 20 Sep 2023 Planned primary completion date changed from 31 Aug 2023 to 1 Apr 2024.